{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:44:07Z","timestamp":1759657447083,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ctrv.2020.102027","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:13:25Z","timestamp":1588608805000},"page":"102027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?"],"prefix":"10.1016","volume":"87","author":[{"given":"Daan G.","family":"Knapen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derk Jan A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmy I.M.","family":"Meijne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf S.N.","family":"Fehrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ctrv.2020.102027_b0005","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102027_b0010","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"10105","key":"10.1016\/j.ctrv.2020.102027_b0015","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102027_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2020.102027_b0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9504","article-title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon-\u03b12b for resected high-risk melanoma","volume":"37","author":"Tarhini","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102027_b0030","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography-an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102027_b0035","series-title":"Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2","first-page":"245","author":"National Research Council of the National Academies","year":"2006"},{"key":"10.1016\/j.ctrv.2020.102027_b0040","doi-asserted-by":"crossref","first-page":"k4931","DOI":"10.1136\/bmj.k4931","article-title":"International variation in radiation dose for computed tomography examinations: prospective cohort study","volume":"364","author":"Smith-Bindman","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2020.102027_b0045","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/annonc\/mdy217","article-title":"ESMO Consensus Conference Guidelines on testicular germ cell cancer: diagnosis, treatment and follow-up","volume":"29","author":"Honecker","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102027_b0050","unstructured":"NCCN Testicular Cancer Version 1.2020. Accessed at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf [on October 10, 2019]."},{"key":"10.1016\/j.ctrv.2020.102027_b0055","first-page":"22","article-title":"Radiological protection in biomedical research. ICRP Publication 62","author":"ICRP","year":"1992","journal-title":"Ann ICRP"},{"issue":"6","key":"10.1016\/j.ctrv.2020.102027_b0060","doi-asserted-by":"crossref","first-page":"W336","DOI":"10.2214\/AJR.17.17984","article-title":"Whole-body MRI: current applications in oncology","volume":"209","author":"Morone","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102027_b0065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacr.2013.03.002","article-title":"Current methods of monitoring radiation exposure from CT","volume":"10","author":"Talati","year":"2013","journal-title":"J Am Coll Radiol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102027_b0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2203\/dose-response.10-003.Cuttler","article-title":"Commentary on using LNT for radiation protection and risk assessment","volume":"8","author":"Cuttler","year":"2010","journal-title":"Dose Response"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102027_b0075","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.117.206219","article-title":"The BEIR VII estimates of low-dose radiation health risks are based on faulty assumptions and data analyses: A call for reassessment","volume":"59","author":"Siegel","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2020.102027_b0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mrrev.2018.04.001","article-title":"Progress in low dose health risk research: Novel effects and new concepts in low dose radiobiology","volume":"776","author":"Averbeck","year":"2018","journal-title":"Mutat Res"},{"key":"10.1016\/j.ctrv.2020.102027_b0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(12)60815-0","article-title":"Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study","volume":"380","author":"Pearce","year":"2012","journal-title":"Lancet"},{"issue":"37","key":"10.1016\/j.ctrv.2020.102027_b0090","first-page":"1","article-title":"Recommendations of the international commission on radiological protection","volume":"2007","author":"ICRP Publication 103","year":"2007","journal-title":"Ann ICRP"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:08Z","timestamp":1759656128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":18,"alternative-id":["S0305737220300657"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102027","relation":{},"ISSN":["0305-7372"],"issn-type":[{"type":"print","value":"0305-7372"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102027"}}